Person:
Mas Zubiri, Alicia

Profile Picture
First Name
Alicia
Last Name
Mas Zubiri
URI
https://hdl.handle.net/20.500.14352/84522
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Veterinaria
Department
Sanidad Animal
Area
Identifiers
UCM identifierScopus Author IDDialnet ID

Filters

2015 - 20193
Reset filters

Settings

Author: Fuente López, Ricardo De La × End date: 2019 ×

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Alternative strategy for visceral leishmaniosis control: HisAK70-Salmonella Choleraesuis-pulsed dendritic cells
    (Comparative Immunology, Microbiology and Infectious Diseases, 2017) Carrión Herrero, Francisco Javier; Domínguez Bernal, Gustavo Ramón; Martínez Rodrigo, Abel; Mas Zubiri, Alicia; Blanco Gutiérrez, María Del Mar; Orden Gutiérrez, José Antonio; Fuente López, Ricardo De La
    Here, we describe a novel approach that exploits an attenuated mutant of Salmonella enterica serovar Choleraesuis as carrier to deliver a plasmid encoding protein HisAK70. Subsequently, dendritic cells (DCs) were pulsed with this vaccine vector. The aim of this study was to evaluate the effectiveness of the prepared HisAK70-S. Choleraesuis-pulsed DCs (HisAK70-SAL DCs) against visceral leishmaniosis (VL). In our ex vivo model of infection, the prepared formulations could decrease parasite growth by up to 80% by augmenting the production of IL-12p40 and by reducing arginase activity (ARG). Also, BALB/c mice when immunised with this formulation showed significant reduction in parasite burden in both spleen (20% of reduction) and liver (75% of reduction). The balance of the immune ratios IFN-γ/IL-10, TNF-α/IL-10, and IgG2a/IgG1 reflected the acquisition of an improved resistant phenotype in HisAK70-SAL DCs vaccinated mice compared to control mice. Our results suggest that HisAK70-SAL DCs could be a promising alternative approach for vaccine delivery that has the potential to fight Leishmania infantum (L. infantum) infection.
  • Thumbnail Image
    Item
    Strength and medium-term impact of HisAK70 immunization in dogs: Vaccine safety and biomarkers of effectiveness for ex vivo Leishmania infantum infection
    (Comparative Immunology, Microbiology and Infectious Diseases, 2019) Martínez Rodrigo, Abel; Mas Zubiri, Alicia; Fernández-Cotrina, Javier; Belinchón-Lorenzo, Silvia; Orden Gutiérrez, José Antonio; Arias, Pablo; Fuente López, Ricardo De La; Carrión Herrero, Francisco Javier; Domínguez Bernal, Gustavo Ramón
    HisAK70 candidates have successfully been tested in cutaneous (CL) and visceral leishmaniosis (VL) mouse models. Here, we analyse different biomarkers in dog trials after a heterologous immunization strategy with a HisAK70 candidate (plasmid DNA plus adoptive transfer of peripheral blood-derived dendritic cells (DCs) pulsed with the same pathoantigen and CpG ODN as an adjuvant) to explore the antileishmanial activity in an ex vivo canine co-culture system in the presence of Leishmania infantum parasites. In the canine model, the heterologous HisAK70 vaccine could decrease the infection index in the DC-T cell co-culture system by up to 54% after 30 days and reach almost 67% after 100 days post-immunization, respectively, compared to those obtained in the control group of dogs. The observed security and potential to fight ex vivo L. infantum infection highlight a HisAK70 heterologous immunization strategy as a promising alternative to evaluate its effectiveness against canine VL.
  • Thumbnail Image
    Item
    HisAK70: progress towards a vaccine against different forms of leishmaniosis
    (2015) Carrión Herrero, Francisco Javier; Domínguez Bernal, Gustavo Ramón; Horcajo Iglesias, María Del Pilar; Orden Gutiérrez, José Antonio; Ruiz Santa Quiteria Serrano De La Cruz, José Antonio; Fuente López, Ricardo De La; Mas Zubiri, Alicia; Martínez Rodrigo, Abel; Ordóñez Gutiérrez, Lara
    Background Leishmania major and Leishmania infantum are among the main species that are responsible for cutaneous leishmaniosis (CL) and visceral leishmaniosis (VL), respectively. The leishmanioses represent the second-largest parasitic killer in the world after malaria. Recently, we succeeded in generating a plasmid DNA (pCMV-HISA70m2A) and demonstrated that immunized mice were protected against L. major challenge. The efficacy of the DNA-vaccine was further enhanced by the inclusion of KMP-11 antigen into the antibiotic-free plasmid pVAX1-asd. Methods Here, we describe the use of a HisAK70 DNA-vaccine encoding seven Leishmania genes (H2A, H2B, H3, H4, A2, KMP11 and HSP70) for vaccination of mice to assess the induction of a resistant phenotype against VL and CL. Results HisAK70 was successful in vaccinated mice, resulting in a high amount of efficient sterile hepatic granulomas associated with a hepatic parasite burden fully resolved in the VL model; and resulting in 100 % inhibition of parasite visceralization in the CL model. Conclusions The results suggest that immunization with the HisAK70 DNA-vaccine may provide a rapid, suitable, and efficient vaccination strategy to confer cross-protective immunity against VL and CL.